Missouri is currently home to 1929 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Saint Louis, Kansas City, St. Louis and Springfield. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)
NCT04363684
Recruiting
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) represents the formalized integration of ARTFL (U54 NS092089; funded through 2019) and LEFFTDS (U01 AG045390; funded through 2019) as a single North American research consortium to study FTLD for 2019 and beyond.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/12/2024
Locations: Washinton University in St. Louis, Saint Louis, Missouri
Conditions: Frontotemporal Lobar Degeneration (FTLD), Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), Behavioral Variant Frontotemporal Dementia (bvFTD), Semantic Variant Primary Progressive Aphasia (svPPA), Nonfluent Variant Primary Progressive Aphasia (nfvPPA), FTD With Amyotrophic Lateral Sclerosis (FTD/ALS), Amyotrophic Lateral Sclerosis, Oligosymptomatic PSP (oPSP), C9orf72, GRN Related Frontotemporal Dementia, MAPT Gene Mutation, TBK1 Gene Mutation, Oligosymptomatic Progressive Supranuclear Palsy
Register for Updates
The Role of Oxytocin in the Second Stage of Labor
NCT04303702
Recruiting
This is a randomized controlled trial investigating the utility of oxytocin administration in the second stage of labor.
Gender:
Female
Ages:
All
Trial Updated:
03/12/2024
Locations: Barnes Jewish Hospital, Saint Louis, Missouri
Conditions: Labor Complication
Register for Updates
AZD6738 for Patients With Progressive MDS or CMML
NCT03770429
Recruiting
This research study is studying a research drug called AZD6738 as a possible treatment for Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia .
Gender:
All
Ages:
18 years and above
Trial Updated:
03/12/2024
Locations: Washington University, Saint Louis, Missouri
Conditions: Leukemia, Myelodysplastic Syndrome
Register for Updates
Long-Term Clinical, Immunologic, and Virologic Profiles of Children Who Received Early Treatment for HIV
NCT05154513
Recruiting
IMPAACT 2028 is an observational prospective study to characterize a cohort of early treated children who may participate in future research related to HIV remission or cure. Up to approximately 250 participants will be in the study for approximately seven years. No intervention is provided in the study.
Gender:
All
Ages:
All
Trial Updated:
03/11/2024
Locations: 32017, Children's Mercy Hospital Clinical Research Site, Kansas City, Missouri
Conditions: HIV Infection
Register for Updates
Amygdala Memory Enhancement
NCT05065450
Recruiting
The objective is to understand how amygdala activation affects other medial temporal lobe structures to prioritize long-term memories. The project is relevant to disorders of memory and to disorders involving affect and memory, including traumatic brain injury and post-traumatic stress disorder.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
03/11/2024
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Brain Diseases, Epilepsy, Memory Disorders, Traumatic Brain Injury, Cognitive Impairment, Post Traumatic Stress Disorder
Register for Updates
Dendritic Cells in Patients With Acute or Chronic Skin Graft Versus Host Disease
NCT02611180
Recruiting
Dendritic cells (DCs) serve as sentries for the immune system. DCs recognize foreign compounds (antigens) in the body, which they internalize and process. When DCs uptake foreign antigens, they migrate to secondary lymphoid organs, where the processed antigens are presented to T cells. Various DC subsets with unique cell lineages, surface protein markers, and tissue localization determinants have been identified. For example, Langerhans cells (LCs) and interstitial dendritic cells (intDCs) are... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/11/2024
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Acute Graft-versus-host Disease, Acute GVHD, Chronic Graft-versus-host Disease, Chronic GVHD
Register for Updates
Haploidentical Hematopoietic Stem Cell Transplantation With Ex Vivo TCR Alpha/Beta and CD19 Depletion in Pediatric Hematologic Malignancies
NCT05011422
Recruiting
This single arm pilot phase I study with safety run-in is designed to estimate the safety and efficacy of a familial mismatched or haploidentical hematopoietic stem cell transplantation (haplo-HSCT) using a novel graft modification technique (selective αβ-TCR and CD19 depletion).
Gender:
All
Ages:
30 years and below
Trial Updated:
03/08/2024
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Pediatric Hematologic Malignancies
Register for Updates
Avenir Complete Post-Market Clinical Follow-Up Study
NCT04731077
Recruiting
The main objectives of this study are to confirm the long-term safety, performance and clinical benefits the Avenir Complete femoral stem and its instrumentation when used in primary total, hemi, and revision hip arthroplasty.
Gender:
All
Ages:
20 years and above
Trial Updated:
03/08/2024
Locations: Heartland Regional Medical Center d.b.a. Mosaic Life Care, Saint Joseph, Missouri
Conditions: Osteoarthritis, Hip, Avascular Necrosis of Hip, Avascular Necrosis of the Femoral Head, Post-traumatic; Arthrosis
Register for Updates
A Phase II Trial of Poly-ICLC for Low-Grade Gliomas
NCT04544007
Recruiting
This is a phase II, prospective, longitudinal, multi-center trial of poly-ICLC (Hiltonol ®) treatment for progressive low-grade gliomas in pediatric patients with NF1. The primary objective is to evaluate the efficacy of poly-ICLC in pediatric NF1 patients with progressive low-grade glioma (LGG) as measured by objective tumor response rate (CR+PR) within the first 48 weeks (12 cycles) of therapy. There will also be secondary and exploratory objectives listed in the detailed description below.
Gender:
All
Ages:
22 years and below
Trial Updated:
03/08/2024
Locations: Washington University - St. Louis (Site 900), Saint Louis, Missouri
Conditions: NF1, Low-grade Glioma
Register for Updates
Study of IV VTS-270 for Infantile Liver Disease Associated With Niemann-Pick Disease, Type C
NCT03471143
Recruiting
Niemann-Pick disease, type C (NPC) is a lethal, autosomal recessive, lysosomal storage disorder characterized by neurodegeneration in early childhood and death in adolescence. NPC results from mutation of either the Niemann-Pick C1 disease (NPC1) (~95% of cases) or NPC2 genes. NPC is characterized by the endolysosomal storage of unesterified cholesterol and lipids in both the central nervous system and peripheral tissues such as the liver. Individuals with NPC demonstrate progressive central ner... Read More
Gender:
All
Ages:
6 months and below
Trial Updated:
03/08/2024
Locations: St. Louis Children's Hospital, Saint Louis, Missouri
Conditions: Niemann-Pick Disease, Type C
Register for Updates
Brain Stimulation for Severe Depression
NCT05393622
Recruiting
Chronic intracalvarial cortical stimulation is a minimally invasive method involving the neurosurgical placement of an electrode above the inner table of the skull. Over time, intracalvarial cortical stimulation is intermittently activated to modulate locally and distally connected brain regions. Because of the important role played by the dorsolateral prefrontal cortex in mood regulation, the goal of this study is to apply intracalvarial prefrontal cortical stimulation (IpCS) over the dorsolate... Read More
Gender:
All
Ages:
Between 21 years and 80 years
Trial Updated:
03/07/2024
Locations: Washington University in St Louis School of Medicine, Saint Louis, Missouri
Conditions: Depression Severe
Register for Updates
Ruxolitinib + Allogeneic Stem Cell Transplantation in AML
NCT03286530
Recruiting
This research study is studying a drug that may help decrease the chances of relapse after Allogeneic Stem Cell transplantation for Acute Myeloid Leukemia. The name of the study drug involved in this study is: • Ruxolitinib
Gender:
All
Ages:
Between 60 years and 80 years
Trial Updated:
03/06/2024
Locations: Washington University, Saint Louis, Missouri
Conditions: Acute Myeloid Leukemia, Acute Myeloid Leukemia in Remission, Allogeneic Stem Cell Transplantation
Register for Updates